Overview

A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response

Status:
Unknown status

Trial end date:
2020-10-01

Target enrollment:

Participant gender:

Summary

Comparison of pre-surgical Myocet/ Cyclophosphamide (MC) q3w followed by either MC or Paclitaxel - depending on early response assessment by ultrasound or by toxicity for elderly non frail primary breast cancer patients with increased risk of relapse.

Phase:

Phase 3

Details

Lead Sponsor:

West German Study Group

Collaborators:

TEVA
Teva Pharmaceuticals USA

Treatments:

Albumin-Bound Paclitaxel
Cyclophosphamide
Doxorubicin
Paclitaxel